We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+28.8%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
+$39.4M
Cap. Flow
+$512M
Cap. Flow %
261.81%
Top 10 Hldgs %
65.77%
Holding
51
New
18
Increased
7
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$10.4M
2
SVRA icon
Savara
SVRA
+$9.26M
3
FLNA
Filana Therapeutics
FLNA
+$7.33M
4
FENC icon
Fennec Pharmaceuticals
FENC
+$6.45M
5
CMRX
Chimerix, Inc.
CMRX
+$4.3M

Top Sells

Rank Stock Value
1
CRMD icon
CorMedix
CRMD
+$14.7M
2
CLRB icon
Cellectar Biosciences
CLRB
+$7.86M
3
VRNA
Verona Pharma
VRNA
+$4.69M
4
HELP
Cybin Inc
HELP
+$2.68M
5
OTLK icon
Outlook Therapeutics
OTLK
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRMD icon
26
CALL
CorMedix
CRMD
$588M
$920K 0.47%
183,900
-516,100
-74% -$5.15M
BFRI icon
27
Biofrontera
BFRI
$15.7M
$885K 0.45%
811,918
+316,428
+64% +$299K
KPRX icon
28
Kiora Pharmaceuticals
KPRX
$11.3M
$827K 0.42%
250,555
-5,000
-2% -$17.3K
EWTX icon
29
PUT
Edgewise Therapeutics
EWTX
$4.42B
$808K 0.41%
+237,500
New +$7.56M
OEF icon
30
PUT
iShares S&P 100 ETF
OEF
$19.9B
$404K 0.21%
+200,000
New +$57.2M
QQQ icon
31
PUT
Invesco QQQ Trust
QQQ
$450B
$356K 0.18%
100,000
-50,000
-33% -$25.3M
TLPH icon
32
Talphera
TLPH
$70.1M
$322K 0.16%
613,939
-145,027
-19% -$113K
XNTK icon
33
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
$311K 0.16%
+800,000
New +$163M
NMRA icon
34
PUT
Neumora Therapeutics
NMRA
$306M
$300K 0.15%
+136,600
New +$1.64M
LXRX icon
35
CALL
Lexicon Pharmaceuticals
LXRX
$1.04B
$282K 0.14%
+1,278,900
New +$1.54M
OWLT icon
36
Owlet
OWLT
$153M
$220K 0.11%
49,441
-220,559
-82% -$1.06M
RLMD icon
37
PUT
Relmada Therapeutics
RLMD
$562M
$95K 0.05%
+100,000
New +$244K
RLMD icon
38
Relmada Therapeutics
RLMD
$562M
$52K 0.03%
+100,000
New +$244K
XNTK icon
39
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.05B
$22K 0.01%
+1,400,000
New +$286M
CADL icon
40
PUT
Candel Therapeutics
CADL
$723M
$480 ﹤0.01%
+262,500
New +$1.55M
ABVX
41
Abivax
ABVX
$10.8B
– –
-139,983
Closed -$1.61M
CLRB icon
42
Cellectar Biosciences
CLRB
$20.2M
– –
-122,385
Closed -$7.86M
CLSD
43
DELISTED
Clearside Biomedical
CLSD
– –
-8,481
Closed -$162K
CRMD icon
44
CorMedix
CRMD
$588M
– –
-1,475,000
Closed -$14.7M
DERM icon
45
Journey Medical
DERM
$178M
– –
-105,917
Closed -$598K
FBIO icon
46
Fortress Biotech
FBIO
$109M
– –
-502,828
Closed -$727K
NAMS icon
47
NewAmsterdam Pharma
NAMS
$3.33B
– –
-10,123
Closed -$168K
OTLK icon
48
Outlook Therapeutics
OTLK
$194M
– –
-450,000
Closed -$2.4M
VERU icon
49
Veru
VERU
$35.6M
– –
-269,450
Closed -$2.07M
VOR icon
50
Vor Biopharma
VOR
$1.18B
– –
-3,834
Closed -$53.7K
1
2
3

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Rosalind Advisors held 51 positions worth $196M, up 25% from $156M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Rosalind Advisors deployed $512M of net new capital in Q4 2024, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was UroGen Pharma: 870,000 shares worth $9.27M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $4.69M trimmed.

  • Rosalind Advisors's largest Q4 2024 buy was UroGen Pharma: 870,000 shares worth $9.27M.
  • Rosalind Advisors added most to OptiNose in Q4 2024, an estimated $2.86M increase.
  • Rosalind Advisors's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $4.69M.
  • Rosalind Advisors fully exited CorMedix in Q4 2024, selling an estimated $14.7M.
  • Rosalind Advisors's ten largest holdings make up 66% of its $196M portfolio in Q4 2024.
  • Rosalind Advisors opened 18 new positions and closed 11 in Q4 2024.
  • Rosalind Advisors's portfolio value rose 25% quarter-over-quarter to $196M.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.